{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:49:33Z","timestamp":1792039773381,"version":"4.4.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.lungcan.2025.108585","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T11:02:01Z","timestamp":1747393321000},"page":"108585","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The safety of extended dosing pembrolizumab when compared to traditional dosing: A review and meta-analysis of retrospective studies"],"prefix":"10.1016","volume":"204","author":[{"given":"Prasanth","family":"Sekar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashmitha","family":"Ashok Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8475-3282","authenticated-orcid":false,"given":"Marcin","family":"Dzienis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.lungcan.2025.108585_b0005","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1080\/21645515.2016.1199310","article-title":"Pembrolizumab (Keytruda)","volume":"12","author":"Kwok","year":"2016","journal-title":"Hum Vaccin Immunother."},{"issue":"9","key":"10.1016\/j.lungcan.2025.108585_b0010","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/ijc.33399","article-title":"Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China Study","volume":"148","author":"Wu","year":"2021","journal-title":"Int J Cancer."},{"issue":"9","key":"10.1016\/j.lungcan.2025.108585_b0015","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.lungcan.2025.108585_b0020","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.3389\/fonc.2020.01193","article-title":"Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic?","volume":"10","author":"Sehgal","year":"2020","journal-title":"Front Oncol."},{"key":"10.1016\/j.lungcan.2025.108585_b0025","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejca.2020.02.016","article-title":"A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation","volume":"131","author":"Lala","year":"2020","journal-title":"Eur J Cancer."},{"key":"10.1016\/j.lungcan.2025.108585_b0030","article-title":"KEYNOTE-555 Cohort B: Efficacy, safety, and PK of pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma","volume":"39(15_suppl):9541","author":"Conrad","year":"2021","journal-title":"J Clin Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108585_b0035","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/CJI.0000000000000361","article-title":"A multicentre retrospective analysis of toxicity in 6-weekly versus 3-weekly pembrolizumab","volume":"44","author":"Rowe","year":"2021","journal-title":"J Immunother."},{"issue":"10","key":"10.1016\/j.lungcan.2025.108585_b0040","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.jtho.2022.06.010","article-title":"Safety implications of switching pembrolizumab dosage from 200 mg every 3 weeks to 400 mg every 6 weeks in patients with advanced NSCLC","volume":"17","author":"Higashiyama","year":"2022","journal-title":"J Thorac Oncol."},{"issue":"Suppl","key":"10.1016\/j.lungcan.2025.108585_b0045","article-title":"Retrospective study of the real-world safety profile of extended dosing 6-weekly pembrolizumab in comparison to traditional 3-weekly dosing schedule for treatment of lung cancer and melanoma in a Queensland hospital","volume":"34","author":"Sekar","year":"2023","journal-title":"Ann Oncol."},{"key":"10.1016\/j.lungcan.2025.108585_b0050","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13690-023-01215-y","article-title":"Methods for meta-analysis and meta-regression of binomial data: concepts and tutorial with Stata command metapreg","volume":"82","author":"Nyaga","year":"2024","journal-title":"Arch Public Health."},{"key":"10.1016\/j.lungcan.2025.108585_b0055","article-title":"Real-world comparison between 6 weeks versus 3 weeks adjuvant pembrolizumab in high-risk stage IIB-IIID cutaneous malignant melanoma: Experience from an academic cancer center","volume":"41(16_suppl):9545","author":"Shah","year":"2023","journal-title":"J Clin Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2025.108585_b0060","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/oncolo\/oyad182","article-title":"Pembrolizumab every 6 weeks versus every 3 weeks in advanced non-small cell lung cancer","volume":"28","author":"Dub\u00e9-Pelletier","year":"2023","journal-title":"Oncologist."},{"key":"10.1016\/j.lungcan.2025.108585_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/S0169-5002(22)00144-1","article-title":"Real-world use of different pembrolizumab regimens (3 weekly versus 6 weekly) in non-small cell lung cancer (NSCLC) patients","author":"Osborne","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108585_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113344","article-title":"Comparison of three-weekly and six-weekly pembrolizumab United Kingdom prescribing practice for advanced and resected melanoma","volume":"194","author":"Mehta","year":"2023","journal-title":"Eur J Cancer."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108585_b0075","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cllc.2021.12.005","article-title":"Safety and Efficacy of Extended Interval Dosing for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer During the COVID-19 Pandemic","volume":"23","author":"Hijmering-Kappelle","year":"2022","journal-title":"Clin Lung Cancer."},{"key":"10.1016\/j.lungcan.2025.108585_b0080","article-title":"A study of the efficacy and toxicity outcomes of extended durvalumab dosing in patients with stage III unresectable non-small cell lung cancer (NSCLC) during the COVID-19 pandemic","volume":"34","author":"Moffat","year":"2023","journal-title":"Cancer Treat Res Commun."},{"key":"10.1016\/j.lungcan.2025.108585_b0085","article-title":"P34.01 6-Weekly vs 3-Weekly Pembrolizumab \u2013 Toxicities and Tolerance in The COVID-era","volume":"16(10):60","author":"Douglas","year":"2021","journal-title":"J Thorac Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2025.108585_b0090","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1093\/annonc\/mdw174","article-title":"Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer","volume":"27","author":"Chatterjee","year":"2016","journal-title":"Ann Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2025.108585_b0095","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1158\/1078-0432.CCR-18-1449","article-title":"The first-week proliferative response of peripheral blood PD-1-positive CD8-positive T cells predicts the response to anti-PD-1 therapy in solid tumors","volume":"25","author":"Kim","year":"2019","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108585_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108775","article-title":"A real-world study on the safety of the extended dosing schedule for nivolumab and pembrolizumab in patients with solid tumors","volume":"108","author":"Morimoto","year":"2022","journal-title":"Int Immunopharmacol."},{"key":"10.1016\/j.lungcan.2025.108585_b0105","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3389\/fphar.2017.00730","article-title":"Immune-related adverse events associated with anti-PD-1\/PD-L1 treatment for malignancies: a meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Front Pharmacol."}],"updated-by":[{"DOI":"10.1016\/j.lungcan.2026.109598","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T00:00:00Z","timestamp":1788652800000}},{"DOI":"10.1016\/j.lungcan.2026.109598","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000}}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225004775?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225004775?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T20:22:32Z","timestamp":1753993352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225004775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":21,"alternative-id":["S0169500225004775"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108585","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The safety of extended dosing pembrolizumab when compared to traditional dosing: A review and meta-analysis of retrospective studies","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108585","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2025 Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108585"}}